Epigral Ltd

- No explicit mention of new fundraising through debt or equity in the call transcript. - Current net debt stands at INR 944 crore as of December 31, 2023, increased by INR 81 crore since March 31, 2023, primarily due to INR 323 crore capital expenditure. - Management indicated that the current debt level is at its peak and is expected to reduce over time through strong cash flows starting next year. - Future capital expenditure planned around INR 300-350 crore annually will be funded by internal accruals and existing cash flows. - No plans were disclosed for equity fundraising; debt levels are expected to remain stable or reduce gradually. - Free cash flow generated post CapEx will be used partly for debt repayment and dividend distribution. - Overall, the company aims to maintain a stable debt level aligned with expansion plans without immediate new debt or equity issuance.

- Ongoing continuous CapEx planned around INR 300-350 crore annually for growth and expansion. - Current CapEx for the year is approximately INR 323 crore, partially funded by internal accruals. - New plants and products expected to be commissioned by end of Q4 FY24. - Future CapEx includes around INR 200 crore for a Chlorotoluene derivative block (similar 15,000-ton size). - Continuous investment in R&D for new chemical chemistries, with a new R&D center established in Ahmedabad. - Capacity expansions: CPVC compound capacity with 50% utilization expected by H1 FY25. - Company targets 25% ROCE on new projects and aims to maintain CapEx aligned with medium-term revenue/EBITDA guidance, with possible ±10-15% variations. - CapEx to turnover ratio for specialty chemical plants expected around 1.4 to 1.5. - Maintenance CapEx estimated at 1.5-2% of plant value per year.

- Epigral Limited expects volume growth driven by new products commissioned in FY23 such as Epichlorohydrin and CPVC Resin. - Additional capacity of CPVC Resin (45,000 tons per annum), CPVC compound (35,000 tons per annum), and Chlorotoluenes value chain will be commissioned, targeting growth in FY25 and FY26. - Revenue contribution from derivative and specialty segment increased to 42% in nine months FY24 versus 27% in the prior year and is expected to rise further due to future expansions focused on these high-growth products. - The company anticipates consistent top-line and bottom-line growth through diversification and multi-product catering to various industries. - Long-term demand outlook for the chemical and manufacturing sectors in India remains positive despite short-term pressure and destocking. - Capacity utilization is expected to optimize by H1 FY25 for newer capacities like CPVC Resin, contributing to sales growth.

Future growth expectations for Epigral Limited as per the Q3 FY24 earnings call: - Target consistent growth in both top line and bottom line driven by expansion and diversification into multi-product segments. - Continuous CapEx plans of around INR 300-350 crore annually to support volume growth and new capacity commissions. - New capacities to be commissioned include 45,000 tons p.a. of CPVC Resin, 35,000 tons p.a. of CPVC Compound, and Chlorotoluenes value chain expansions, driving growth in FY25 and FY26. - Management maintains a target ROCE of around 25% when undertaking new projects. - Volume growth witnessed: 18% YoY in Q3 FY24 and 17% for nine months of FY24, driven by recently commissioned products like Epichlorohydrin and CPVC Resin. - EBITDA margin improved QoQ from 23% to 26% due to higher capacity utilization and operational efficiencies. - Long-term outlook remains positive; current challenges viewed as short-term disruptions. Overall, management is optimistic about sustained earnings and margin expansion through strategic capacity additions and product diversification.

The transcript does not explicitly mention the current or expected order book or pending orders for Epigral Limited in Q3 FY24. However, insights related to business growth and project status include: - Focus on future expansion and diversification targeting consistent top-line and bottom-line growth. - Ongoing projects are near completion (85%-90%) with expected completion by the end of Q4 FY24. - No revenue contribution expected from these projects in the current financial year. - Continuous CapEx of INR 300-350 crore planned annually for growth. - Ramp-up in capacity utilization in key products like Epichlorohydrin, expected to improve from Q4 onwards. - Strategy includes import substitution in niche chemical products (e.g., Chlorotoluene derivatives) targeting replacement of import volume of 15,000 tons by FY26. For detailed order book or pending orders data, the transcript does not provide specific figures or updates.